Skip Navigation LinksHome > December 1, 2013 - Volume 64 - Issue 4 > Impact of Autologous Dendritic Cell–Based Immunotherapy (AGS...
JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/QAI.0b013e3182a4b9ad
Brief Report: Basic and Translational Science

Impact of Autologous Dendritic Cell–Based Immunotherapy (AGS-004) on B- and T-Cell Subset Changes and Immune Activation in HIV-Infected Patients Receiving Antiretroviral Therapy

Jenabian, Mohammad-Ali DVM, PhD*; Nicolette, Charles A. PhD; Tcherepanova, Irina Y. PhD; DeBenedette, Mark A. PhD; Gilmore, Norbert MD, PhD*; Routy, Jean-Pierre MD*,‡

Collapse Box


Abstract: We previously reported that a combination of antiretroviral therapy with 4 monthly injections of each patient's own autologous dendritic cells (AGS-004) electroporated with CD40 ligand and with HIV RNA antigens obtained from each patient's own pre-antiretroviral therapy plasma induced HIV-specific CD8 T-cell responses in 10 patients. To assess other AGS-004–induced immune changes, we evaluated the modifications in B- and T-cell subsets and the level of immune activation in these patients. The proportion of Bm1 naive cells was increased along with an augmentation of the proliferation marker Ki67. Memory B-cell frequency, CD4 and CD8 T-cell subsets, regulatory T-cell frequency, and CD38/HLA-DR/PD-1 T-cell activation levels remained unchanged after AGS-004 dendritic cell immunotherapy.

© 2013 by Lippincott Williams & Wilkins


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.